230 related articles for article (PubMed ID: 33096421)
1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V; Paz-Ares L; Besse B; Moreno V; Peters S; Sala MA; López-Vilariño JA; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Zaman K; López R; Ponce S; Boni V; Arrondeau J; Delord JP; Martínez M; Wannesson L; Antón A; Valdivia J; Awada A; Kristeleit R; Olmedo ME; Rubio MJ; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D' Arcangelo M; Santoro A; Villalobos VM; Sands J; Trigo J
Lung Cancer; 2020 Dec; 150():90-96. PubMed ID: 33096421
[TBL] [Abstract][Full Text] [Related]
2. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
[TBL] [Abstract][Full Text] [Related]
4. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
[TBL] [Abstract][Full Text] [Related]
5. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
[TBL] [Abstract][Full Text] [Related]
7. Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Fernández-Teruel C; Fudio S; Lubomirov R
Cancer Chemother Pharmacol; 2022 May; 89(5):585-594. PubMed ID: 34739582
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
Boyne DJ; Dawe DE; Shakir H; Joe-Uzuegbu O; Farah E; Pabani A; Baratta C; Brenner DR; Cheung WY
Target Oncol; 2023 Sep; 18(5):697-705. PubMed ID: 37656263
[TBL] [Abstract][Full Text] [Related]
10. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
[TBL] [Abstract][Full Text] [Related]
12. Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
Rittberg R; Leung B; Al-Hashami Z; Ho C
Curr Oncol; 2022 Dec; 29(12):9744-9752. PubMed ID: 36547179
[TBL] [Abstract][Full Text] [Related]
13. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
14. A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
Cheng Y; Wu C; Wu L; Zhao J; Zhao Y; Chen L; Xin Y; Zhang L; Pan P; Li X; Li J; Dong X; Tang K; Gao E; Yu F
Sci Rep; 2024 Feb; 14(1):3598. PubMed ID: 38351146
[TBL] [Abstract][Full Text] [Related]
15. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
Singh S; Jaigirdar AA; Mulkey F; Cheng J; Hamed SS; Li Y; Liu J; Zhao H; Goheer A; Helms WS; Wang X; Agarwal R; Pragani R; Korsah K; Tang S; Leighton J; Rahman A; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 May; 27(9):2378-2382. PubMed ID: 33288660
[TBL] [Abstract][Full Text] [Related]
17. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R; Rengarajan B; Naveh N; Boccuti A; Park JE; Adeyemi A; Caisip C; Jansen JP; Wilson FR
J Comp Eff Res; 2023 May; 12(5):e220098. PubMed ID: 37079341
[No Abstract] [Full Text] [Related]
18. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
[TBL] [Abstract][Full Text] [Related]
19. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
[TBL] [Abstract][Full Text] [Related]
20. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
Patel S; Petty WJ; Sands JM
Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
